Esophageal Ca Survival Jumps with Docetaxel
SAN FRANCISCO (MedPage Today) -- Second-line chemotherapy with docetaxel for esophagogastric cancer led to a greater than 40% improvement in survival compared with only symptomatic treatment, results of a British study showed.
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Esophagus Cancer | Gastroenterology | Study | Taxotere